Produced by Araxis Merge on 11/9/2017 4:31:03 PM Central Standard Time. See www.araxis.com for information about Merge. This report uses XHTML and CSS2, and is best viewed with a modern standards-compliant browser. For optimum results when printing this report, use landscape orientation and enable printing of background images and colours in your browser.
# | Location | File | Last Modified |
---|---|---|---|
1 | PPS-N_B397.zip\PPS-N_B397\PPS-N_B397\PS_PPS_interface\src\test\resources\xml\document\test | orderCheckResponse1.xml | Thu Nov 9 15:09:02 2017 UTC |
2 | PPS-N_B397.zip\PPS-N_B397\PPS-N_B397\PS_PPS_interface\src\test\resources\xml\document\test | orderCheckResponse1.xml | Thu Nov 9 21:01:57 2017 UTC |
Description | Between Files 1 and 2 |
|
---|---|---|
Text Blocks | Lines | |
Unchanged | 3 | 248 |
Changed | 2 | 4 |
Inserted | 0 | 0 |
Removed | 0 | 0 |
Whitespace | |
---|---|
Character case | Differences in character case are significant |
Line endings | Differences in line endings (CR and LF characters) are ignored |
CR/LF characters | Not shown in the comparison detail |
No regular expressions were active.
1 | <?xml | |
2 | version="1 .0" | |
3 | encoding=" UTF-8" | |
4 | ?> | |
5 | <PEPSRespo nse | |
6 | xmlns="gov /va/med/ph armacy/pep s/external /common/pr eencapsula tion/vo/dr ug/check/r esponse" | |
7 | > | |
8 | ||
9 | <Header> | |
10 | ||
11 | <Time | |
12 | value="084 5" | |
13 | /> | |
14 | ||
15 | <MServer | |
16 | namespace= "VISTA" | |
17 | uci="text" | |
18 | ip=" IP " | |
19 | ||
20 | serverName ="Server N ame" | |
21 | stationNum ber="45" | |
22 | /> | |
23 | ||
24 | <MUser | |
25 | userName=" REDACTED " | |
26 | duz="88660 079" | |
27 | jobNumber= "1001" | |
28 | /> | |
29 | ||
30 | <PEPSVersi on | |
31 | difIssueDa te="200810 20" | |
32 | difBuildVe rsion="6" | |
33 | difDbVersi on="3.2" | |
34 | /> | |
35 | ||
36 | </Header> | |
37 | ||
38 | <Body> | |
39 | ||
40 | <drugCheck > | |
41 | ||
42 | <drugDrugC hecks> | |
43 | ||
44 | <drugDrugC heck> | |
45 | ||
46 | <interacte dDrugList> | |
47 | ||
48 | <drug | |
49 | orderNumbe r="Z;2;Pro spect" | |
50 | ien="455" | |
51 | gcnSeqNo=" 25485" | |
52 | /> | |
53 | ||
54 | <drug | |
55 | orderNumbe r="Z;1;Pro spect" | |
56 | ien="113" | |
57 | vuid="7788 99" | |
58 | gcnSeqNo=" 266" | |
59 | /> | |
60 | ||
61 | </interact edDrugList > | |
62 | ||
63 | <severity> | |
64 | Contraindi cated Drug Combinati on | |
65 | </severity > | |
66 | ||
67 | <interacti on> | |
68 | SELECTED P ROTEASE IN HIBITORS/A MIODARONE | |
69 | </interact ion> | |
70 | ||
71 | <shortText > | |
72 | INDINAVIR SULFATE OR AL CAPSULE 400 MG an d AMIODARO NE HCL ORA L TABLET 2 00 MG may interact b ased on th e potentia l interact ion betwee n SELECTED PROTEASE INHIBITORS and AMIOD ARONE. | |
73 | </shortTex t> | |
74 | ||
75 | <professio nalMonogra ph> | |
76 | ||
77 | <monograph Source> | |
78 | FDB | |
79 | </monograp hSource> | |
80 | ||
81 | <disclaime r> | |
82 | This infor mation is generalize d and not intended a s specific medical a dvice. Con sult your healthcare professio nal before taking or discontin uing any d rug or com mencing an y course o f treatmen t. | |
83 | </disclaim er> | |
84 | ||
85 | <monograph Title> | |
86 | MONOGRAPH TITLE: Se lected Pro tease Inhi bitors/Ami odarone | |
87 | </monograp hTitle> | |
88 | ||
89 | <severityL evel> | |
90 | SEVERITY L EVEL: 1-C ontraindic ated Drug Combinatio n: This dr ug combina tion is co ntraindica ted and ge nerally sh ould not b e dispense d or admin istered to the same patient. | |
91 | </severity Level> | |
92 | ||
93 | <mechanism OfAction> | |
94 | MECHANISM OF ACTION: Indinavi r,(1) nelf inavir,(2) ritonavir ,(3) and t ipranavir coadminist ered with ritonavir( 4) may inh ibit the m etabolism of amiodar one at CYP P-450-3A4 . | |
95 | </mechanis mOfAction> | |
96 | ||
97 | <clinicalE ffects> | |
98 | CLINICAL E FFECTS: T he concurr ent admini stration o f amiodaro ne with in dinavir,(1 ) nelfinav ir,(2) rit onavir,(3) or tipran avir coadm inistered with riton avir(4) ma y result i n increase d levels, clinical e ffects, an d toxicity of amioda rone. | |
99 | </clinical Effects> | |
100 | ||
101 | <predispos ingFactors > | |
102 | PREDISPOSI NG FACTORS : None de termined. | |
103 | </predispo singFactor s> | |
104 | ||
105 | <patientMa nagement> | |
106 | PATIENT MA NAGEMENT: The concu rrent admi nistration of amioda rone with indinavir, (1) nelfin avir(2), r itonavir,( 3) or tipr anavir coa dministere d with rit onavir(4) is contrai ndicated b y the manu facturers of indinav ir,(1) nel finavir(2) , ritonavi r,(3) and tipranavir coadminis tered with ritonavir . (4) | |
107 | </patientM anagement> | |
108 | ||
109 | <discussio n> | |
110 | DISCUSSION : Indinav ir has bee n shown to inhibit C YP P-450-3 A4. There fore, the manufactur er of indi navir stat es that th e concurre nt adminis tration of indinavir with amio darone, wh ich is met abolized b y CYP P-45 0-3A4, is contraindi cated.(1)N elfinavir has been s hown to in hibit CYP P-450-3A4. Therefor e, the man ufacturer of nelfina vir states that the concurrent administr ation of n elfinavir with amiod arone, whi ch is meta bolized by CYP P-450 -3A4, is c ontraindic ated.(2)Ri tonavir ha s also bee n shown to inhibit C YP P-450-3 A4. Theref ore, the m anufacture r of riton avir state that the concurrent administr ation of r itonavir w ith amioda rone is co ntraindica ted.(3) | |
111 | </discussi on> | |
112 | ||
113 | <reference s> | |
114 | <![CDATA[R EFERENCES: 1.Crixivan (indinavi r sulfate) US prescr ibing info rmation. M erck & Co. , Inc. Jul y, 2007.2. Viracept ( nelfinavir mesylate) US prescr ibing info rmation. A gouron Pha rmaceutica ls, Inc. J uly, 2007. 3.Norvir ( ritonavir) US prescr ibing info rmation. A bbott Labo ratories A ugust, 200 8.4.Aptivu s (tiprana vir) US pr escribing informatio n. Boehrin ger Ingelh eim Pharma ceuticals, Inc. June , 2008.]]> | |
115 | </referenc es> | |
116 | ||
117 | </professi onalMonogr aph> | |
118 | ||
119 | </drugDrug Check> | |
120 | ||
121 | </drugDrug Checks> | |
122 | ||
123 | </drugChec k> | |
124 | ||
125 | </Body> | |
126 | </PEPSResp onse> |
Araxis Merge (but not the data content of this report) is Copyright © 1993-2016 Araxis Ltd (www.araxis.com). All rights reserved.